NIPPON CHEMIPHAR CO., LTD. Logo

NIPPON CHEMIPHAR CO., LTD.

Develops generic drugs, allergy treatments, and novel pharmaceuticals for a global market.

4539 | T

Overview

Corporate Details

ISIN(s):
JP3701600003
LEI:
Country:
Japan
Address:
千代田区岩本町二丁目2番3号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Nippon Chemiphar Co., Ltd. is a pharmaceutical company engaged in the manufacture, sale, import, and export of ethical pharmaceuticals, diagnostic agents, and health-related products. The company's business is centered on three strategic pillars: the development of high-quality generic drugs; the commercialization of innovative products derived from its core technologies in the allergy field; and the creation of novel drugs based on proprietary technologies and know-how, such as alkalization therapy. Nippon Chemiphar aims to provide solutions that help people maintain their health and is actively pursuing the global expansion of its three core business areas.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-13 02:32
Report Publication Announcement
確認書
Japanese 8.7 KB
2025-11-13 02:32
Interim Report
半期報告書-第94期(2025/04/01-2026/03/31)
Japanese 221.2 KB
2025-06-20 03:58
Post-Annual General Meeting Information
臨時報告書
Japanese 30.9 KB
2025-06-20 03:57
Governance Information
内部統制報告書-第93期(2024/04/01-2025/03/31)
Japanese 23.8 KB
2025-06-20 03:57
Registration Form
確認書
Japanese 8.6 KB
2025-06-20 03:56
Registration Form
有価証券報告書-第93期(2024/04/01-2025/03/31)
Japanese 1.2 MB
2024-11-13 01:21
Interim Report
半期報告書-第93期(2024/04/01-2025/03/31)
Japanese 223.1 KB
2024-11-13 01:21
Interim Report
確認書
Japanese 8.7 KB
2024-06-24 08:03
Regulatory News Service
臨時報告書
Japanese 18.7 KB
2024-06-24 03:28
Post-Annual General Meeting Information
臨時報告書
Japanese 25.6 KB
2024-06-24 03:27
Registration Form
確認書
Japanese 8.6 KB
2024-06-24 03:26
Governance Information
内部統制報告書-第92期(2023/04/01-2024/03/31)
Japanese 23.2 KB
2024-06-24 03:24
Registration Form
有価証券報告書-第92期(2023/04/01-2024/03/31)
Japanese 1.2 MB
2024-02-13 04:31
Report Publication Announcement
確認書
Japanese 8.7 KB
2024-02-13 04:30
Quarterly Report
四半期報告書-第92期第3四半期(2023/10/01-2023/12/31)
Japanese 230.5 KB

Automate Your Workflow. Get a real-time feed of all NIPPON CHEMIPHAR CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for NIPPON CHEMIPHAR CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for NIPPON CHEMIPHAR CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Apellis Pharmaceuticals, Inc. Logo
Developing novel C3 therapies for diseases in ophthalmology, nephrology, and hematology.
United States of America
APLS
Apimeds Pharmaceuticals US, Inc. Logo
Biopharma developing non-narcotic bee venom therapies for osteoarthritis pain and inflammation.
United States of America
APUS
Apogee Therapeutics, Inc. Logo
Developing novel antibody biologics for immunological and inflammatory (I&I) diseases.
United States of America
APGE
Apollomics Inc. Logo
A clinical-stage biopharma developing targeted oncology therapies for hard-to-treat cancers.
United States of America
APLM
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany
APPH
Develops DNA tech for genetic medicine, molecular diagnostics, and supply chain security.
United States of America
APDN
Applied Therapeutics, Inc. Logo
Develops treatments for rare metabolic and central nervous system (CNS) disorders.
United States of America
APLT
Aprea Therapeutics, Inc. Logo
Developing precision cancer therapies targeting DNA Damage Response for solid tumors.
United States of America
APRE
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.
South Korea
397030
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologic drugs and biosimilars for the professional market.
South Korea
003060

Talk to a Data Expert

Have a question? We'll get back to you promptly.